EUVIMEDEUVIMED entdecken
Crossref

Vogt-Koyanagi-Harada Disease: The Clinical Spectrum and Management of Case Series in a Tertiary Eye Centre in Northern Part Of Malaysia

Atiqah Nur Hasan, Mushawiahti Mustapha, Haslina Abdul Halim Wan Wan

Czech and Slovak Ophthalmology · 2024

DOI: 10.31348/2024/1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Czech and Slovak Ophthalmology, 2024. Verfasst von Atiqah Nur Hasan und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Uveomeningoencephalitic Syndrome. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We present the clinical spectrum, the initial clinical presentation with management trends in treating 14 Vogt-Koyanagi-Harada (VKH) disease cases in a tertiary center in the Northern part of Malaysia. Case series: There were 14 cases of Vogt-Koyanagi-Harada (VKH) disease retrospectively reviewed over five years (from 2015 to 2020). The mean age at presentation was 37.7 years (range 21–64 years), with female predominance (85.7%). All cases presented with acute uveitic stage and bilateral eye involvement. Of them, 11 (78.6%) were probable VKH, and three (21.4%) were incomplete VKH. All patients attended with acute panuveitis at first presentation. The main posterior segment involvement was disc edema in 57.1% (16 out of 28 eyes) and exudative retinal detachment (ERD) in 35.7% (10 out of 28 eyes). Most of them presented with blindness (3/60 and worse) and moderate visual impairment (6/18–6/60); 35.71% each, followed by mild visual impairment (6/12-6/18), and severe visual impairment (6/60–3/60); 7.1% each. Ten patients (71.4%) required combination second-line immunomodulatory treatment during subsequent visits, and only four patients (28.6%) responded well to corticosteroid therapy. Most of the cases achieved no visual impairment (64.3%), followed by mild visual impairment (21.4%) and moderate visual impairment (14.3%), and none were severe or blind at the end of follow-up.

Conclusion

VKH is a potentially blinding illness if there is inadequate control of the disease in the acute stage. Most of our patients achieved good visual outcomes with early immunomodulatory treatment and systemic corticosteroids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uveomeningoencephalitic SyndromeHumansFemaleYoung AdultAdultMiddle AgedMaleRetrospective StudiesMalaysiaGlucocorticoidsVision DisordersBlindness

Stichwörter der Autor:innen

Vogt-Koyanagi-Harada Diseaseimmunomodulatorycorticosteroidpanuveitis

Substanzen

Glucocorticoids

Zitieren

APA

Hasan, A. N., Mustapha, M., & Wan, H. A. H. W. (2024). Vogt-Koyanagi-Harada Disease: The Clinical Spectrum and Management of Case Series in a Tertiary Eye Centre in Northern Part Of Malaysia. Czech and Slovak Ophthalmology. https://doi.org/10.31348/2024/1

Vancouver

Hasan AN, Mustapha M, Wan HAHW. Vogt-Koyanagi-Harada Disease: The Clinical Spectrum and Management of Case Series in a Tertiary Eye Centre in Northern Part Of Malaysia. Czech and Slovak Ophthalmology. 2024. doi:10.31348/2024/1

BibTeX
@article{Hasan2024,
  author = {Hasan, Atiqah Nur and Mustapha, Mushawiahti and Wan, Haslina Abdul Halim Wan},
  title = {Vogt-Koyanagi-Harada Disease: The Clinical Spectrum and Management of Case Series in a Tertiary Eye Centre in Northern Part Of Malaysia},
  journal = {Czech and Slovak Ophthalmology},
  year = {2024},
  doi = {10.31348/2024/1}
}
Kostenlos starten →